Informations sur le produit
Osimertinib dimesylate is a novel oral, selective inhibitor of MET protein tyrosine kinase. It has been shown to be selectively toxic to tumor cells that express the MET protein tyrosine kinase and is an effective agent for the treatment of metastatic and/or locally advanced solid tumors. Osimertinib dimesylate has been shown to inhibit tumor growth in vivo in xenograft models, including those with acquired resistance to other agents.
MET inhibition has been shown to cause tumor regression in some cases. The molecular target of osimertinib dimesylate is the MET receptor tyrosine kinase, which is overexpressed in many cancers.
MET inhibition leads to downstream signaling events leading to cell cycle arrest and apoptosis induction. The drug also inhibits RNA synthesis by binding directly to ribosomes as well as DNA synthesis by binding directly to DNA polymerases, resulting in a potent antitumor activity against various cancer types
Propriétés chimiques
Question d’ordre technique sur : 3D-VHD01482 Osimertinib dimesylate
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages
